加拿大中度至重度炎症性肠病患者的先进疗法的治疗模式:回顾性队列分析
Laura Targownik1, Waqqas Afif2, Sunny Singh3
1Department of Gastroenterology & Hepatology, University of Toronto, Mount Sinai Hospital, 600 University avenue, Toronto, ON M5G 1X5, Canada.
Journal of the Canadian Association of Gastroenterology
|February 5, 2025
概括
许多炎症性肠病 (IBD) 患者因缺乏疗效而停止先进疗法. 这项研究发现,一线先进治疗的中位持续时间为克罗恩病的12.3个月,性结肠炎的9.2个月.
科学领域:
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
- 现实世界的证据 现实世界的证据
背景情况:
- 许多患有炎症性肠病 (IBD) 的患者对先进疗法反应不足或失去反应.
- 目前的指导方针建议优化剂量和切换疗法,以实现最佳的治疗反应.
研究的目的:
- 评估在中度至重度IBD患者中不同治疗序列的持续性.
- 分析现实世界的治疗模式和优化策略,用于先进的疗法.
主要方法:
- 加拿大患者的回顾性队列研究 (RECORDED) 中度至重度的性结肠炎 (UC) 或克罗恩病 (CD).
- 纳入标准:在2015/2016年5月至2021年4月期间接触过多种先进疗法.
- 主要终点:第一个先进治疗的终止时间.
主要成果:
- 该研究包括330名CD和344名UC患者.
- 终止第一线先进治疗的中位时间为12.3个月 (CD) 和9.2个月 (UC).
- 缺乏疗效是改变治疗的最常见原因,58.1% (CD) 和59.1% (UC) 的患者在停止治疗之前优化了第一线治疗.
结论:
- 来自加拿大的现实数据显示,IBD的第一线先进疗法持久性有限.
- 缺乏疗效经常需要改变治疗方法,通常涉及转换到不同的药物类别.
- 优化治疗是常见的,但往往不足以防止停止治疗.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
306
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
306
Inflammatory Bowel Disease IV: Pharmacological Management
100
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
100


